Abstract:Objective: Although the mechanisms behind pharmacokinetic (PK) drug-drug interactions (DDIs) are well-documented, bridging the gap between this knowledge and clinical evidence of DDIs, especially for serious adverse drug reactions (SADRs), remains challenging. While leveraging the FDA Adverse Event Reporting System (FAERS) database along with disproportionality analysis tends to detect a vast number of DDI signals, this abundance complicates further investigation, such as validation through clinical trials. Our study proposed a framework to efficiently prioritize these signals and assessed their reliability using multi-source Electronic Health Records (EHR) to identify top candidates for further investigation. Methods: We analyzed FAERS data spanning from January 2004 to March 2023, employing four established disproportionality methods: Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagating Neural Network (BCPNN). Building upon these models, we developed four ranking models to prioritize DDI-SADR signals and cross-referenced signals with DrugBank. To validate the top-ranked signals, we employed longitudinal EHRs from Vanderbilt University Medical Center and the All of Us research program. The performance of each model was assessed by counting how many of the top-ranked signals were confirmed by EHRs and calculating the average ranking of these confirmed signals. Results: Out of 189 DDI-SADR signals identified by all four disproportionality methods, only two were documented in the DrugBank database. By prioritizing the top 20 signals as determined by each of the four disproportionality methods and our four ranking models, 58 unique DDI-SADR signals were selected for EHR validations. Of these, five signals were confirmed. The ranking model, which integrated the MGPS and BCPNN, demonstrated superior performance by assigning the highest priority to those five EHR-confirmed signals. Conclusion: The fusion of disproportionality analysis with ranking models, validated through multi-source EHRs, presents a groundbreaking approach to pharmacovigilance. Our study's confirmation of five significant DDI-SADRs, previously unrecorded in the DrugBank database, highlights the essential role of advanced data analysis techniques in identifying ADRs.

Timing Matters: A Machine Learning Method for the Prioritization of Drug–Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure

Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects

Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records

A Bayesian method to detect drug‐drug interaction using external information for spontaneous reporting system

A novel algorithm for analyzing drug-drug interactions from MEDLINE literature

Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data

A simulation-based comparison of drug-drug interaction signal detection methods

Propensity score‐adjusted three‐component mixture model for drug‐drug interaction data mining in FDA Adverse Event Reporting System

Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports

A Comprehensive Review of Computational Methods for Drug-drug Interaction Detection

A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance

Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events

Drug—drug interaction through molecular structure similarity analysis

Thinking Three-Dimensionally: A Self- and Externally-Controlled Approach to Screening for Drug-Drug-Drug Interactions Among High-Risk Populations

Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions

Systematic Prediction of Pharmacodynamic Drug-Drug Interactions Through Protein-Protein-Interaction Network.

Informatics confronts drug–drug interactions

Data Mining and Analytical Models to Predict and Identify Adverse Drug-drug Interactions

Analysis and prediction of drug–drug interaction by minimum redundancy maximum relevance and incremental feature selection

Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively?